ESMO 2018 | Positive results for trastuzumab biosimilar CT-P6 in HER2+ early breast cancer

There are currently five trastuzumab biosimilars in development, this is a remarkable and positive advancement in the treatment of breast cancer. Justin Stebbing, MD, from Imperial College London, London, UK, discusses the development of CT-P6. His involvement started during pre-clinical studies and has continued into Phase I and most recently a Phase III trial (NCT02162667) evaluating the efficacy and safety of CT-P6 in HER2+ early breast cancer. Prof. Stebbing describes the results in detail, emphasizing the positive pathological complete response rates and the safety profile with regards to left ventricular ejection fraction, which was similar to the originator. He hopes that such positive results will have a beneficial impact in the future by reducing treatment costs and therefore making this treatment available to more patients. This interview was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany.